Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.55 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | TET3 | O43151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.51 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.51 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.51 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.51 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.51 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19878264 | 0.90 | RAB9A (0.68) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16118421 | 0.83 | NPC1 (0.55) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11123314 | 0.81 | KCNH2 (0.56) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13182918 | 0.81 | NPC1 (0.59) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1531725 | 0.80 | KCNH2 (0.59) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27888979 | 0.80 | KCNH2 (0.73) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL27863722 | 0.79 | KCNH2 (0.58) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19976603 | 0.78 | CPB1 (0.58) | TEAD3TEAD1HSD11B1TET3KMT2A | |
| SCHEMBL1193744 | 0.77 | KCNH2 (0.56) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1473424 | 0.77 | QDPR (0.61) | KCNH2HRH3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| CN-110785426-A | Compositions and methods for modulating PPP2R1A | 加利福尼亚大学董事会 | 2020-02-11 | — | — | CN | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
| WO-2018144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144869-A1 | COMPOSITONS AND METHODS FOR MODULATING UBA5 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144871-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | RTN4, RTN3, RCN1 | KCNH2 4443/4885HRH3 2558/4885NPC1 2442/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | KCNH2 4879/4885HRH3 3251/4885NPC1 37/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | KCNH2 4868/4885HRH3 2858/4885NPC1 2966/4885 |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | PPP2R1A, PPP3CA, PPP2R2A | KCNH2 4713/4885HRH3 4544/4885NPC1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.